More patients with POMS have no new or newly enlarged (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) treatment compared with interferon β-1a (IFNβ-1a) treatment, and the annual recurrence rate is lower than DMF, according to a study published online on September 28 at JAMA Open Network.

Patrick Vermeersch, MD, PhD, of the Lille University Hospital Center in France, and colleagues conducted an open-label, randomized, active-controlled clinical trial in patients with PMS between the ages of 10 and

The researchers found that among the 103 participants who completed the study, the proportion of patients without N or NE T2 hyperintense lesions at week 96 was 16.1 percent and 4.9 percent for DMF and IFNβ-1a, respectively; in a sensitivity analysis among the treatment-planned population, the proportions were 12.8 and 2.8 percent, respectively. The estimated proportion of patients who did not relapse was 66.2 and 52.3 percent, respectively, for DMF and IFNβ-1a at week 96. Adjusted annual recurrence rates were 0.24 and 0.53 for DMF and IFNβ-1a, respectively, at week 96; the rate ratio was 0.46 for DMF versus IFNβ-1a.

“The CONNECT randomized clinical trial showed that DMF resulted in significant improvements in radiographic and clinical outcomes in patients with POMS, with a positive benefit-risk ratio,” the authors wrote.

Several authors have disclosed financial ties to biopharmaceutical companies, including Biogen, which manufactures dimethyl fumarate and funded the lawsuit.

Transdermal CBD is no better than placebo in drug-resistant focal epilepsy

Additional information:
Patrick Vermeersch et al., Effects of dimethyl fumarate versus interferon β-1a in patients with childhood-onset multiple sclerosis, JAMA Open Network (2022). DOI: 10.1001/jamanetworkopen.2022.30439

Omar Abdel-Manan and others. Considering the future of pediatric multiple sclerosis research following the open-label, randomized CONNECT trial, JAMA Open Network (2022). DOI: 10.1001/jamanetworkopen.2022.30451

Copyright © 2022 Health Day. All rights reserved.

Citation: Comparison of Pediatric Multiple Sclerosis Treatments (2022, October 6) Retrieved October 6, 2022 from

This document is subject to copyright. Except in good faith for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.